Background {#Sec1}
==========

Within the USA, type 2 diabetes mellitus (T2DM) and its precursor, prediabetes, are growing public health concerns. Approximately 84 million adults have prediabetes \[[@CR1]\], and it is estimated that one-third of the adult population will have T2DM by 2050 \[[@CR2]\]. Diabetes Prevention Programs (DPPs) can promote modest weight loss \[[@CR3]--[@CR8]\] to help individuals with prediabetes avoid progression to T2DM \[[@CR9]--[@CR11]\], and these programs are available in communities throughout the USA \[[@CR4], [@CR12]\].

Despite nationwide availability of the DPP \[[@CR4]\] and public health initiatives to identify and treat individuals with prediabetes \[[@CR13], [@CR14]\], rates of DPP engagement are extremely low \[[@CR15]\]. Barriers to DPP participation include logistical factors (e.g., transportation, time, cost) \[[@CR16]\] and behavioral factors (e.g., motivation, risk perception) \[[@CR17]--[@CR19]\]. Although web-based DPPs \[[@CR20], [@CR21]\] and growing insurance coverage for program participation \[[@CR22]--[@CR24]\] can reduce logistical barriers, these strategies alone have been inadequate to increase rates of DPP engagement. In September 2015, for example, a single University's self-funded health insurers began to offer face-to-face and online DPP options to healthcare plan members (i.e., employees, retirees, and students of the University or their dependents) with prediabetes at no out-of-pocket-cost, yet only 6% of invitees enrolled in a DPP within 6 months. Prior work demonstrates an association between greater levels of autonomous motivation and increased engagement in healthy behaviors among this university's employees with prediabetes \[[@CR25]\]. This finding, in combination with low levels of program engagement, suggests that behavioral barriers may more strongly influence rates of DPP participation than logistical ones.

New strategies are needed to motivate individuals with prediabetes to engage in healthy behaviors to prevent T2DM. Mobile health (mHealth) technologies that incorporate principles from behavioral change theories such as Self-Determination Theory (SDT) may be an effective and highly scalable approach \[[@CR26]\]. SDT provides a conceptual framework for understanding human behavior across a continuum of motivation ranging from controlled motivation to autonomous motivation \[[@CR27]\]. In contrast to controlled motivation, which originates from a sense of external obligation or pressure, goals and behaviors are "autonomous" when they align with personal interests and values \[[@CR28]\]. Greater levels of autonomous motivation correlate positively with dietary adherence \[[@CR29]\], weight loss \[[@CR30], [@CR31]\], physical activity \[[@CR32], [@CR33]\], and DPP participation \[[@CR34]\]. Importantly, autonomous behaviors are sustained over time \[[@CR35], [@CR36]\].

JOOL Health is a mobile phone-based health application that aims to increase autonomous motivation by helping users connect certain health behaviors (e.g., sleep, diet, physical activity) with personal values in specific life domains (e.g., family and work) \[[@CR37]\]. JOOL Health integrates user-entered information with contextual data (e.g., weather and day of the week) and then delivers tailored messages to help individuals gain awareness of and control over the factors that contribute to their well-being and ability to engage in self-care behaviors. In this way, JOOL Health aims to cultivate autonomous sources of motivation to initiate and maintain healthy behaviors. Importantly, the JOOL Health application has been tested among heterogeneous populations including healthy volunteers and individuals with chronic diseases. These unpublished data demonstrate high user engagement and statistically significant increases in self-reported health behaviors.

We propose a pilot study to estimate the ability of JOOL Health---used alone and also in conjunction with Fitbit devices (i.e., activity tracker and wireless internet-enabled scale)---to increase autonomous motivation to prevent T2DM among individuals with prediabetes who declined participation in a formal DPP (i.e., DPP non-participants). Given that JOOL Health draws on SDT to inspire behavioral change, we hypothesize that autonomous motivation to prevent T2DM will increase to a greater degree among individuals who use JOOL Health compared to individuals who only receive written educational materials about T2DM prevention. Because Fitbit devices can also enhance user motivation by fostering autonomy, competence, and relatedness (through sharing of fitness data) \[[@CR38]\]---key SDT tenets of psychological need---we also hypothesize that autonomous motivation to prevent T2DM will increase to a greater degree among individuals who use JOOL Health in conjunction with Fitbit devices compared to individuals who use the JOOL Health application alone. Further, we aim to examine the feasibility of recruiting DPP non-participants and the acceptability (adherence and qualitative experience as reported during semi-structured interviews) of the intervention. We hypothesize that recruiting DPP non-participants may have unique challenges, as these individuals have already declined to participate in one lifestyle intervention. However, as compared to the DPP, this is a low-intensity intervention, which may appeal to individuals seeking a less time-consuming program, and we believe that study participants will find the intervention acceptable. Taken together, these data will inform the design and implementation of a larger trial to test the effect of JOOL Health on clinically relevant outcomes, including weight loss, physical activity, and DPP engagement.

Methods {#Sec2}
=======

This study was approved by the University of Michigan Institutional Review Board. The protocol was designed according to the Standard Protocol Items: Recommendations for Interventional Trials 2013 (SPIRIT). A SPIRIT figure (Fig. [1](#Fig1){ref-type="fig"}) and SPIRIT checklist (Additional file [1](#MOESM1){ref-type="media"}) are provided. The study is funded by the Blue Cross Blue Shield of Michigan Foundation, and it is registered on [ClinicalTrials.gov](http://clinicaltrials.gov) (NCT03025607).Fig. 1Study flow diagram

Study design {#Sec3}
------------

This study is a 12-week pilot randomized controlled trial. Participants will be randomized to one of three arms: (1) a group that receives information on prediabetes and evidence-based ways to decrease progression to T2DM as well as a list of resources for mHealth tools for monitoring diet, physical activity, and weight (comparison); (2) a group that receives the same information as group 1 and also the JOOL Health mobile phone application (JOOL-only); and (3) a group that receives the same information as group 1 and also the JOOL Health mobile phone application and Fitbit devices (i.e., activity tracker and wireless internet-enabled scale) whose results can be uploaded to JOOL Health (JOOL-plus). We will use a mixed methods approach with a sequential explanatory design, which is to say that quantitative data and qualitative data will be collected in two consecutive phases within the study \[[@CR39]\]. Specifically, in the first phase, we will collect and analyze the quantitative data (e.g., surveys and weight). In the second phase, we will collect and analyze qualitative, semi-structured interview data from a purposive sample of 20 participants with differing levels of engagement and success with the intervention. The rationale for this approach is that the qualitative data will help to clarify these findings by exploring participants' experiences and perspectives in more depth \[[@CR40]\]. Additionally, through qualitative interviews, we will explore the acceptability of the JOOL Health application among JOOL-only participants and the acceptability of the JOOL Health application and Fitbit devices among the JOOL-plus participants.

Study setting {#Sec4}
-------------

The intervention will be delivered remotely. Individuals in each arm of the study will receive study materials by postal mail and/or e-mail. A study team member will be available by telephone to help participants troubleshoot technical issues that may arise with the study devices and to address study-related questions or concerns.

Study participants {#Sec5}
------------------

Inclusion criteria are (1) non-participation in a formal DPP at least 6 months after invitation to participate by the University's self-funded insurers, Premier Care or Grad Care; (2) prediabetes based on the American Diabetes Association criteria of hemoglobin A1c (HbA1c) 5.7 to 6.4%; (3) access to a personal smartphone; and (4) access to home wireless internet. We will exclude women who are pregnant or intend to become pregnant during the intervention period. All eligible study participants are employees, retirees, and students of this university or their dependents.

Recruitment {#Sec6}
-----------

A member of the study team will contact by telephone a random subset of Premier Care and Grad Care DPP non-participants. Individuals interested in study participation will then be screened to ensure they meet study eligibility criteria, and informed consent will be obtained electronically using the RedCap survey platform \[[@CR41]\].

Allocation {#Sec7}
----------

Individuals who meet study inclusion criteria and consent to study participation will be randomized using a web-based tool, the University of Michigan computerized randomization system (TATUM---Treatment Assignment Tool-UM), which allows for blinded treatment allocation. We will use stratified randomization with variable block lengths to ensure a balance of age and gender between groups. Recruitment and randomization will be ongoing until we have 35 individuals in each arm of the study.

Intervention {#Sec8}
------------

All participants (*N* = 105) will receive information regarding prediabetes, evidence-based T2DM prevention strategies, and mHealth resources to help monitor food intake and composition, weight, and physical activity (e.g., MyFitnessPal). All participants will be encouraged to engage in self-monitoring and will be provided information on the benefits of daily weighing and monitoring of food and physical activity.

Participants in the JOOL-only and JOOL-plus arms will receive instruction by e-mail on how to use their respective mHealth applications. Participants in both intervention arms will be asked to use JOOL Health on a daily basis. JOOL Health will deliver tailored messages to individuals based on the daily information they enter in the following behavioral health domains: sleep, presence, activity, creativity, and eating. Additionally, the tailored messaging will be informed by contextual factors (e.g., local weather and day of the week). Participants in the JOOL-plus arm will also be asked to perform daily weights using a Fitbit wireless internet-enabled scale and to wear a Fitbit physical activity tracker. These devices will interface with the JOOL Health platform, and the data will inform JOOL-delivered tailored messages.

Outcome measures {#Sec9}
----------------

### Primary outcome measures {#Sec10}

The primary outcome will be change in autonomous motivation to prevent T2DM. Autonomous motivation will be measured using the seven-item, validated Treatment Self-Regulation Questionnaire at baseline and 12-week follow-up \[[@CR42]\].

### Secondary outcome measures {#Sec11}

The feasibility of recruitment will be determined by calculating the intervention uptake rate, defined as the number of participants recruited to the intervention divided by the total number of eligible participants. Because we may not be able to reach all eligible participants via telephone (e.g., disconnected phone line), we will also calculate the rate of intervention uptake among only those for whom we are able to contact. Reasons for non-participation in this study will be recorded.

Among JOOL-only and JOOL-plus participants, we will calculate rates of adherence to the JOOL Health application, defined as the number of app-usage days (defined as the number of days that users entered data into JOOL Health) divided by the total number of days during the intervention period. Among JOOL-plus participants, we will calculate rates of participant adherence to the Fitbit activity tracker and scale, defined as the number of total days that each of these devices were used divided by the total number of days during the intervention period.

Participant retention will be determined by calculating the completion rate for the 12-week survey.

The acceptability of the intervention will be determined through semi-structured interviews conducted via telephone. Following the intervention period, we will conduct semi-structured interviews with JOOL-only and JOOL-plus participants. For purposive sampling, we will interview individuals with differing levels of engagement with the intervention and change in autonomous motivation using cut-points for high and low levels of these determined following quantitative data analysis. We will conduct at least 20 interviews divided equally between JOOL-only and JOOL-plus participants; additional interviews will be conducted if we do not reach thematic saturation after 20 interviews \[[@CR43], [@CR44]\]. During the interviews, we will explore the following: reasons participants chose to engage in this study; participants' experience with the JOOL Health application; and participants' experiences with the Fitbit activity tracker and scale, if applicable. In this way, we will gain insight into the particular intervention characteristics (or combination of characteristics) that may have facilitated or hindered the participants' ability to achieve the primary outcome. We will also solicit participants' ideas regarding additional behavioral change supports and their recommendations on ways to improve the intervention.

We will evaluate change in HbA1c; baseline HbA1c will be abstracted from the electronic medical record and participants will be asked to have a follow-up HbA1c drawn after the 12-week intervention period. Additional exploratory outcomes will include change in the following self-reported measures: weight (kg) and/or BMI (kg/m^2^); change in overall level of motivation to prevent T2DM \[[@CR34]\]; purpose in life \[[@CR45], [@CR46]\]; perceived competence to prevent type 2 diabetes \[[@CR47]\]; social support \[[@CR48]\]; eating behavior \[[@CR49]\]; self-reported physical activity \[[@CR50]\]; patient activation \[[@CR51]\]; and willingness to participate in a Diabetes Prevention Program. We will collect these exploratory data at baseline and 12-weeks using survey instruments, which will be administered using RedCap, a secure web application \[[@CR52]\]. At baseline, we will also collect sociodemographic characteristics including age, gender, race, ethnicity, education, and income. Among JOOL Health users, we will also evaluate changes in charted daily health behaviors (e.g., sleep, eating, physical activity) from baseline (first 2 weeks of the intervention) to 12-weeks (last 2 weeks of the intervention). Among participants in the JOOL-plus arm, we will also assess objective change in physical activity minutes and body weight as measured with the Fitbit activity tracker and scale from baseline (first 2 weeks of the intervention) to 12-weeks (last 2 weeks of the intervention). Because the Fitbit devices interface with the JOOL Health platform, Fitbit data will be stored within the JOOL Health application. At the end of the study period, the JOOL Health team will provide our study team with a comma-separated values (CSV) file containing raw data from the JOOL app and Fitbit devices.

Sample size {#Sec12}
-----------

Based on prior studies of autonomous motivation among University of Michigan employees \[[@CR34]\], we anticipate that the baseline level of autonomous motivation to prevent T2DM among Premier Care or Grad Care members who decline DPP participation will be 5.7 (measured on a 1 to 7 scale with 1 being the lowest and 7 being the highest). During the 12-week intervention period, we anticipate that autonomous motivation will increase by 0.6 points in the JOOL-only arm and by 0.8 points in the JOOL-plus arm. Assuming a standard deviation of 1.0 for change in autonomous motivation in both arms, 29 participants in each arm will provide 80% power to detect these changes in autonomous motivation in the intervention arms compared to the comparison arm. Prior research demonstrates that a 0.5-point increase in autonomous motivation can lead to greater weight loss and increased physical activity compared to individuals who did not achieve this increase in autonomous motivation \[[@CR36]\]. To account for the possibility that some participants may be lost to follow-up during our 12-week intervention, we have conservatively inflated our sample size by 20% to enroll 35 participants in each arm.

Data analysis {#Sec13}
-------------

For all continuous outcomes, we will calculate changes from baseline to 12 weeks. For each continuous outcome, we will then conduct two sample *t* tests to determine whether the mean change for that outcome was statistically significantly different for each intervention arm relative to the comparison arm. For all categorical outcomes, we will use chi-square or Fisher's exact tests to between-arm changes from baseline to 12 weeks. While we will be conducting multiple tests for statistical significance, we will not adjust our threshold for statistical significance (e.g., using a Bonferroni correction) for multiple comparisons so as to avoid making a type II error in this pilot study. We will conduct all analyses using Stata 14.

Semi-structured interviews will be audio recorded and subsequently transcribed verbatim. Interviews will then be imported into qualitative analysis software. Two investigators will independently read and code transcribed interviews. Interviews will then be coded jointly using consensus conferences. Interviews will be analyzed using directed content analysis \[[@CR53]\].

Consistent with a mixed-methods sequential explanatory design \[[@CR40]\], we will integrate (i.e., connect) the quantitative and qualitative findings in the final stage of data analysis. In this way, we will interpret our quantitative data in the context of qualitative participant experience.

Discussion {#Sec14}
==========

Evidence-based Diabetes Prevention Programs are available in communities across the USA and can effectively promote weight loss among individuals with prediabetes \[[@CR12]\]. However, the DPP alone may be insufficient to improve population health, as low rates of participation limit the program's reach. Prior studies have described determinants of participation \[[@CR17]\] and non-participation \[[@CR16], [@CR54], [@CR55]\] in lifestyle-change programs, as well as barriers to adherence among those who initially engage in these programs \[[@CR19]\]. However, it is unknown whether interventions to increase levels of autonomous motivation---a key driver of lifestyle change among individuals with prediabetes \[[@CR25]\]---can promote healthy behaviors and greater rates of DPP engagement among individuals with prediabetes.

In this pilot study, we aim to test whether JOOL Health can increase autonomous motivation among individuals with prediabetes when used alone and also in conjunction with other mHealth tools. Because changes in individuals' levels of autonomous motivation occur early along the path to behavioral change, we anticipate a large effect size from the intervention and will therefore have the power to detect between-group differences in this outcome in the context of a relatively small study (*N* = 105). This will serve as an important indicator that a larger study may lead to measurable changes in clinically relevant health outcomes such was body weight, physical activity, and DPP engagement. It is also possible that we will not detect changes in autonomous motivation. For this reason, we will conduct qualitative interviews with study participants so that we can interpret our quantitative findings in the context of individual-level participant experiences. For example, it is possible that some individuals may desire additional support (e.g., brief counseling, nutritional advice, explicit exercise goals) to augment the JOOL Health experience. Some individuals may want more tailored messaging from the JOOL Health application while others may find the daily charting to be burdensome. Understanding participants' experiences will enable us to refine and strengthen our program. In this way, we will tailor our intervention to better meet the individual-level needs of this previously overlooked population with prediabetes who have not engaged in a formal DPP.

Importantly, we will also gain new insight into the feasibility of recruiting a target population that is presumed to be difficult to engage based on extremely low rates of uptake in offered DPP options. However, it is plausible that some individuals, although reluctant to engage in a year-long DPP, may be interested in a lower-intensity program such as this mHealth intervention. Relatively high levels of engagement in this intervention may suggest that this population is not as difficult to reach as presumed. Rather, tailored strategies and varied options to encourage weight loss and increased physical activity may be needed to help such individuals prevent type 2 diabetes. In contrast, relatively low levels of engagement may confirm our suspicion that this is truly a difficult population to engage, and we could then consider focus groups and/or interviews with key stakeholders to explore best practices for engagement.

This study has several important potential limitations. First, this is, to our knowledge, the first study to test a behavioral change program among individuals who previously declined DPP participation despite being invited to participate in either an in-person or web-based option at no out-of-pocket-cost. Accordingly, it is difficult to predict rates of recruitment or adherence among this population, as these individuals may be more reluctant to make lifestyle changes than the general population, and additional strategies may be necessary to encourage participation. We will thus collect data about the intervention's feasibility and acceptability, and we will apply learned lessons to the subsequent larger study. Second, despite numerous mHealth applications to promote behavioral change and chronic disease management, rates of engagement with these applications over time are low \[[@CR56]\], and use of mHealth devices may have unpredictable effects on the behaviors and outcomes they aim to modify \[[@CR57], [@CR58]\]. It is unknown whether study participants will engage with JOOL Health or whether use of the app will stimulate positive behavioral change among the study population. Encouragingly, JOOL Health possesses key features associated with app effectiveness (e.g., user-friendly design, real-time feedback, and individualized messages) \[[@CR59]\], which we believe will facilitate app use and promote healthy behaviors. Lastly, our study population will only include members of the University of Michigan's self-funded insurance plans, which may limit the generalizability of our findings. To minimize this limitation, we will recruit from a random sample of health plan beneficiaries with prediabetes, which includes over 20,000 employees, dependents, and retirees.

To reduce the public health burden of prediabetes and T2DM, novel strategies are needed to promote healthy behaviors among individuals with prediabetes. The information gathered through this study will inform subsequent work to identify clinically effective, cost-effective, and highly-scalable approaches to prevent or delay the onset of T2DM and enhance the population health impact of existing Diabetes Prevention Programs.
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DPP

:   Diabetes Prevention Program

HbA1c

:   Hemoglobin A1c

mHealth

:   Mobile health

SDT

:   Self-Determination Theory

T2DM

:   Type 2 diabetes mellitus

**Electronic supplementary material**

The online version of this article (10.1186/s40814-018-0246-z) contains supplementary material, which is available to authorized users.

Dr. Hafez acknowledges support from the Robert Wood Johnson Foundation in her role as a Clinical Scholar. The authors acknowledge support from the National Institute of Diabetes and Digestive and Kidney Diseases (P30DK092926). Dr. Kullgren is a VA HSR&D Career Development awardee at the Ann Arbor VA. Dr. Kullgren also received grants from the Robert Wood Johnson Foundation, from the US Department of Veterans Affairs, and from the Donaghue Foundation.

*The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US government.*

Funding {#FPar1}
=======

This research is funded by the Blue Cross Blue Shield Foundation of Michigan, the National Med-Peds Residency Association, and the Robert Wood Johnson Clinical Scholars Program.

Availability of data and materials {#FPar2}
==================================

Data is not anticipated to be publically available. Study materials are available from authors on request.

All authors contributed to the design of the intervention. DHG drafted the manuscript, which was reviewed, edited, and approved by all the co-authors. All authors made intellectual contributions to the work. All authors read and approved the final manuscript.

Authors' information {#FPar3}
====================

Dr. Griauzde is an Internal Medicine physician and a second year research fellow in the Robert Wood Johnson Foundation's Clinical Scholars Program (VA Scholar).

Ethics approval and consent to participate {#FPar4}
==========================================

This study was approved by the Institutional Review Board at the University of Michigan.

Consent for publication {#FPar5}
=======================

It is not applicable; individual participant's data will not be included in any form.

Competing interests {#FPar6}
===================

Drs. Griauzde, Heisler, and Richardson declare that they have no competing interests. Dr. Kullgren has received consulting fees from SeeChange Health and HealthMine, and a speaking honorarium from AbilTo, Inc.

Publisher's Note {#FPar7}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
